Business Wire - Indications for Merck’s SINGULAIR® Expand with FDA Approval for Perennial Allergic Rhinitis; SINGULAIR Now Shown to Provide Relief from a Broad Range of…
Tuesday, October 7th, 2008WHITEHOUSE STATION, N.J. — Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SINGULAIR(R) (montelukast sodium) for the relief of symptoms of perennial allergic rhinitis (PAR), or indoor allergies, in adults and children six months of age and older. A convenient once-a-day tablet, SINGULAIR has been proven to help relieve a broad ra…
